Strategies for the safe use of non-steroidal anti-inflammatory drugs
10.5124/jkma.2018.61.6.367
- Author:
Ga Young AHN
1
;
Sang Cheol BAE
Author Information
1. Department of Rhuematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. scbae@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Anti-inflammatory agents, non-steroidal;
Drug-related side effects and adverse reactions;
Medication therapy management
- MeSH:
Anti-Inflammatory Agents, Non-Steroidal;
Aspirin;
Cardiovascular System;
Celecoxib;
Digestive System;
Drug-Related Side Effects and Adverse Reactions;
Hematology;
Hemorrhage;
Humans;
Medication Therapy Management;
Prescriptions;
Prostaglandin-Endoperoxide Synthases;
Risk Factors
- From:Journal of the Korean Medical Association
2018;61(6):367-375
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in various clinical situations, with excellent analgesic, anti-pyretic and anti-inflammatory effects. In addition to gastrointestinal bleeding, which was the first adverse effect to be reported, myriad adverse effects from the digestive system, cardiovascular system, renal system and hematology have been also reported. In early 2000s, a few new cyclooxygenase (COX)-2 selective inhibitors were developed with the expectation of better gastrointestinal safety profile, most of them were withdrawn from the market due to various adverse effects, and interest in safety of NSAIDs has been increased again. Over the past two decades, research on the safety and adverse effects of NSAIDs has accumulated. In brief, celecoxib is associated with fewer gastrointestinal adverse events compared to non-selective NSAIDs. In patients receiving aspirin, the use of non-selective NSAIDs should be avoided, and if an anti-inflammatory drug is required, a COX-2 selective inhibitor should be considered. Celecoxib has been shown to have similar or better safety profile than other non-selective COX inhibitors. Additionally, the new COX-2 selective inhibitors of etorixocib and polmacoxib have been approved. Many factors should be considered when prescribing NSAIDs, as the safety profile of indivisual NSAIDs vary, and NSAIDs have a high risk of duplicate prescription because of the variety of indications and over-the-counter products. Physicians should comprehend the updated guidelines and the results of new clinical studies, and the risk factors for each individual patient should also be reviewed. Physicians should therefore contemplate new prescription strategies.
